Lack of response to imatinib mesylate as second-line therapy in a patient with C-kit positive metastatic soft tissue leiomyosarcoma [1]

Tumori

Volumn 91, Issue 1, 2005, Pages 103-

  Silvestris, Nicola ^a   Parra, Hector Soto ^b   Angelini, Francesco ^a   Di Cosimo, Serena ^a   D'Aprile, Modesto ^a   Santoro, Armando ^b  

^a Operative Unit of Medical Oncology   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DACARBAZINE; EPIRUBICIN; IFOSFAMIDE; IMATINIB; STEM CELL FACTOR RECEPTOR;

ADULT; CANCER CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LETTER; LUNG METASTASIS; MALE;

EID: 16344378795     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160509100123     Document Type: Letter

References (6)

1. Singer S, Demetri GD, Baldini EH, eFletcher CD: Management of soft-tissue sarcoma: an overview and update. Lancet Oncol, 1: 75-85, 2000.
2. Savage DG, Antman KH: Imatinib mesylate - a new oral target therapy. N Engl J Med, 346: 683-693, 2002.
3. Merchant MS, Woo CW, Mackall CL, Thiele CJ: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst, 94: 1673-1679, 2002.
4. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571. Oncogene, 19: 3521-3528, 2000.
5. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer, 39: 2006-2011, 2003.
6. Hotfilder M, Lanvers C, Jurgens H, Boos J, Vormoor J: C-kit-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer Chemother Pharmacol, 50: 167-169, 2002.